What was Vimizim’s (elosulfase alfa) launch price in 2014?
Public launch-price information for Vimizim in 2014 can vary by country and by whether the figure quoted refers to list price, net price, or price-per-vial/price-per-year. The only specific detail provided in your question is “2014 380,000,” which looks like an amount tied to that year, but there isn’t enough context here (currency and country) to confirm what that number means.
If you tell me the country (for example, US, UK, Germany, France, etc.) and the currency (or the source document you’re using), I can pin down the correct “launch price” figure and explain how the 380,000 amount is defined (per year, per infusion, per vial, etc.).
Where does the “380,000” figure usually come from?
In pricing tables, “launch price” numbers are often presented as:
- an annual cost (for an average patient dosing assumption), or
- a per-unit price (per vial) plus an annual consumption estimate.
To verify whether “380,000” matches an annual figure or a unit price, I need the country/currency and the packaging/dosing basis used by the source you’re looking at.
Can Vimizim pricing differ after launch?
Yes. Even around the launch period, pricing can change because of:
- tender/discount structures,
- national reimbursement negotiations,
- updates to dosing assumptions in cost-effectiveness models.
So “launch price” is best matched to the initial listed price in a specific jurisdiction and date.
What I need from you to answer precisely
Reply with any of the following and I’ll give a precise answer:
1) Country and currency for the “380,000” (e.g., USD, GBP, EUR)
2) Whether 380,000 is “per year” or “per vial”
3) A link or screenshot of the table where you saw “2014 380 000”
Sources
None (no source text or link was provided in your message).